Recent research has highlighted the potential of growth hormone (GH) therapy to improve height in children who have undergone hematopoietic stem cell transplantation (HCT), a common treatment for various life-threatening cancers and noncancerous conditions. While advances in HCT procedures have significantly increased survival rates among pediatric patients, a growing number of survivors face long-term side effects, with growth impairment and reduced adult height being among the most prevalent.

A comprehensive study conducted by a collaborative team from the Japanese Children's Cancer Group, under the leadership of Hiroshima University, investigated the efficacy of GH therapy in children who experienced post-transplant short stature. Their findings, published in a peer-reviewed medical journal, provide insight into the varying responses to this therapy and factors influencing treatment outcomes.

Extensive Nationwide Cohort Analysis

The research involved a retrospective, multicenter cohort analysis spanning multiple institutions across Japan. A total of 268 pediatric HCT survivors diagnosed with short stature were enrolled, and final adult height data was available for 171 participants. Of these, 58 children received GH therapy, while 113 did not. The study meticulously documented various patient characteristics, including age at diagnosis, age at transplantation, sex, underlying medical conditions, transplant type, and the presence of comorbidities, to identify factors that may impact growth outcomes.

Significant Height Gains with Variable Responses

Analysis revealed that GH therapy was generally associated with improved final adult height in children with post-HCT short stature. However, the degree of improvement varied considerably among patients. The study found that certain transplant-related factors significantly influenced the effectiveness of therapy. In particular, patients who received total body irradiation (TBI) as part of their treatment protocol exhibited lower final height outcomes compared to those who did not receive TBI. TBI is commonly used prior to transplantation to eliminate malignant cells and reduce the risk of transplant rejection, but it also has a known impact on growth and endocrine function.

Another key observation was the persistent, long-term benefit of GH therapy for many recipients. Unlike children with classical GH deficiency, some HCT survivors demonstrated continued height improvements for several years after the initiation of therapy, with measurable gains still evident at five years and at final adult height. This pattern suggests that the underlying mechanisms of growth impairment in HCT survivors may differ from those in other GH-deficient populations.

Differences Based on Transplant Type

The study also explored how the source of transplanted stem cells--whether autologous (from the patient) or allogeneic (from a donor)--affected growth outcomes and response to GH treatment. Findings indicated that children who underwent allogeneic transplantation exhibited different growth patterns compared to those who received autologous transplants, implying that the biological processes underlying post-transplant growth impairment may vary depending on transplant type.

Implications for Personalized Care

Overall, the research demonstrates that while GH therapy offers significant benefits for many childhood HCT survivors with growth impairment, individual responses can differ widely. The results underscore the importance of tailored, long-term management strategies that consider each patient's medical history, treatment exposures, and risk factors. The identification of predictors for poor response, such as exposure to TBI or the development of chronic graft-versus-host disease, could enable clinicians to optimize therapy and improve quality of life for survivors.

Ongoing research aims to further elucidate the biological factors that determine individual responses to GH therapy, with the goal of developing more precise approaches to post-transplant care. As the population of childhood HCT survivors continues to grow, enhancing long-term health and maximizing growth potential remain key objectives in survivorship care.